Combination of azithromycin and hydroxychloroquine led to significant inhibition of viral replication for wells containing hydroxychloroquine at 5 μM in combination with azithromycin at 10 and 5 μM (P-values at 0,0003 for A10H5 and at 0,0004 for A5H5) (Fig
Although the results in these 80 patients were satisfactory, more studies needed to evaluate the risks versus benefits in these patients
Hydroxychloroquine (HCQ), with or without azithromycin (AZ), has been found to have efficacy as a treatment for COVID-19 in some studies [1,2], while other studies have not shown efficacy [3,4]
This study aimed to evaluate the use of hydroxychloroquine and azithromycin combination in treatment
First, combination treatment with hydroxychloroquine and azithromycin was safe and generally well-tolerated
Among the potential solutions currently under investigation, a combination bitherapy consisting of the antimalarial drug, hydroxychloroquine (CLQ-OH) with the antibiotic, azithromycin (ATM) has received particular attention
The trial was pre-terminated due to futility at a pre-planned interim analysis
For the significant associations of hydroxychloroquine + azithromycin vs no drug with cardiac arrest and hydroxychloroquine alone vs azithromycin alone with cardiac arrest, the respective E-values for the lower bound of the OR’s CI of 1
The coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide
have conducted an open-label non-randomized clinical trial to test the efficacy of the combination use of hydroxychloroquine and azithromycin in the treatment of COVID-19 patients